The combination of Vincristine and Crizotinib inhibits tumor cell proliferation and blocks the RAS/MAPK, PI3K/AKT, and JAK/STAT3 signaling pathways in nonsmall cell lung cancer EML4-ALK V1 cells (Sampson et al. 2022). Here, AKT1 is linked to lung cancer.